Clinical Trial Update: Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating second-line systemic therapy in combination with SBRT for hepatocellular carcinoma with oligoprogression after first-line tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Oligoprogression | Phase 2 | Status: NOT_YET_RECRUITING